Julie Gemmill, DO, MS

Assistant Professor of Medicine | PD @SBHemOncFellow | GI Medical Oncologist @SBMed

[Julie Gemmill, DO, MS @JulieGemmill]

🧬 Oncotype DX RS from metastatic breast cancer sites is feasible.
📈 Higher RS, frequent PR loss, and poor match with primary tumors may impact treatment planning.
#BreastCancer #Oncology #PrecisionMedicine https://t.co/Zoz4i2x84n

[Julie Gemmill, DO, MS @JulieGemmill]

🎓 Huge congrats to our graduating Hematology-Oncology fellows — Alessandra, Andrea & Suguna!
Your dedication to advancing cancer care is truly inspiring. Wishing you continued success in this exciting next chapter! 🩸🧬
#HemeOnc #fellowshipgraduation @SBHemOncFellow

[Stony Brook Medicine @StonyBrookMed]

Why get certified? Because excellence is achieved when knowledge meets dedication. Today, we celebrate the incredible commitment of our certified #nurses who go above and beyond to provide the best care to our patients! #CertifiedNursesDay #HealthcareHeroes

[Stony Brook Hematology Oncology Fellowship @SBHemOncFellow]

We are pleased to announce that Dr. Luke Li @StonyBrookMed will be the @SBHemOncFellow Chief Fellow for academic year 2025-2026 👏

[Arndt Vogel @ArndtVogel]

Clinicogenomic landscape of #PDAC identifies KRAS mutant dosage as prognostic of overall survival
@NatureMedicine
https://t.co/t2Z2LOl9Ti
👉Very comprehensive analysis on the impact of KRAS
👉Key for understanding de novo and acquired resistance to RAS 💊
@myESMO

[Julie Gemmill, DO, MS @JulieGemmill]

Celebrating our incredible #HemOncFellows during Fellow Appreciation Month this February! Their intelligence, hard work, and dedication to our patients are truly inspiring, and it's a privilege to work alongside them every day. @SBHemOncFellow @StonyBrookMed #fellowappreciation

[JAMA Internal Medicine @JAMAInternalMed]

Monoclonal gammopathy of unknown significance is common, often discovered incidentally and indolent. This Review summarizes evidence on the diagnosis and management of monoclonal gammopathy of unknown significance to guide clinical decision-making. https://t.co/j21UqnWQj7

[Ryan Nipp, MD, MPH, MBA, FASCO @RyanNipp]

Pilot Randomized Trial of an Educational Intervention About Immunotherapy for Patients With Advanced #Cancer and Their Caregivers.

https://t.co/QWp50gsgB5

@JNCCN @MGHCancerCenter @MGHPalCareGeri
#PallOnc #Immunotherapy #SuppOnc
@lpetrillz

[Julie Gemmill, DO, MS @JulieGemmill]

Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial | Nature Medicine https://t.co/VdXuWBmDWw

[NEJM @NEJM]

Patients with a prothrombotic clinical course often associated with thrombocytopenia may have a monoclonal paraprotein, even at low levels, that activates platelets by binding to platelet factor 4. Read the Brief Report: https://t.co/te1RtMJ17B

[Yakup Ergün @dr_yakupergun]

ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma

https://t.co/ab71DM0NAn

[Ryan Nipp, MD, MPH, MBA, FASCO @RyanNipp]

Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.

https://t.co/O4GoBj9xOO

@ASCO @JCO_ASCO @JCOOP_ASCO
#Immunotherapy #PallOnc #GeriOnc #SuppOnc
@DDoroshow @ElizabethPrsic

[Erman Akkus @Erman_Akkus]

🧬Two-stage molecular testing in pancreatic cancer
@myESMO Gastrointestinal Oncology

✅It may be more feasible and cost-effective than upfront comprehensive profiling

👉https://t.co/tYJCuZZK5V

@OncoAlert #cancer #oncology #MedX

[Oscar Tahuahua @drtahuahua]

Total neoadjuvant treatment, Non-operative management and Radiotherapy-free strategies: New approaches for the management of pMMR/MSS locally advanced rectal cancer.

A comprehensive review and evidence-based algorithm

https://t.co/gMAwbmuXiq

[Julie Gemmill, DO, MS @JulieGemmill]

Full article: Long-term yogurt intake and colorectal cancer incidence subclassified by Bifidobacterium abundance in tumor https://t.co/zEktVUnaw2

[Julie Gemmill, DO, MS @JulieGemmill]

Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data - The Lancet Oncology https://t.co/fNWIojM46Q

[Erman Akkus @Erman_Akkus]

🔵Our study on LDL and metastatic CRC has been published

✅High LDL > colonic primary
❓Although they are considered equal when metastatic, colon and rectal cancers have different biology

🚨In patients treated without curative intent
High LDL > earlier progression
❓ChT, anti-EGFR, anti-VEGF resistance?

👉https://t.co/N6HLw3KgVp

@nemreoksuz @OncoAlert #cancer #Oncology #MedX

[NEJM @NEJM]

A basket study evaluated the efficacy of zenocutuzumab, a bispecific antibody against HER2 and HER3, in patients with solid tumors harboring NRG1 fusions. Among 158 patients, 30% had a response (including 42% with pancreatic cancer).

Full eNRGy study results: https://t.co/3IF5tJFeAl

[Julie Gemmill, DO, MS @JulieGemmill]

Integrative Oncology: Incorporating Evidence-Based Approaches for Patients With GI Cancers | American Society of Clinical Oncology Educational Book https://t.co/34mUvZeMyn

[Stony Brook Hematology Oncology Fellowship @SBHemOncFellow]

“It's such a privilege to start a career in oncology in 2025, because in our lifetime we can expect a paradigm shift from a reactive to a proactive approach in cancer screening, surveillance, and management.” Dr. Suguna Raju and Dr. Luke Li @StonyBrookMed #WorldCancerDay